SBWire

This past November the largest group of Therapists in IAOM-US history sat for certification testing. 30 therapists tested: two in Alaska, three in Wisconsin, seven in Colorado, and eighteen in Texas.

Memory-improvement-techniques.com/pr1.html offers a program that will help everyone to improve and sharpen their minds. The innovative program includes 2 powerful eBooks, namely Memory Improvement Techniques and the Classic Roth Memory Course. This Memory Improvement program is jam packed with different examples and tips that everyone can use in developing their memory in just a short period of time.

CheckPoint Partners, a leader in management consulting services, recently announced a new fixed price business model. This new way of doing business, says spokesperson Corey Gorman, effectively changes the game of high-priced firms like Accenture, KPMG, and EY Delloite.

Companies looking to drive change through strategy and execution often have no clear tools to achieve goals which have been set. CheckPoint Partners has created a 360 degree IT Governance Model which is a toolkit used to characterize and surface risks. Techniques and interventions are used to enhance capabilities necessary to undertake changes which are critical. "The unique assessment process used by CheckPoint Partners identifies the change corridor a company needs to make use of to maximize return on investment," Corey Gorman explains.

Postherpetic Neuralgia - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Postherpetic Neuralgia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia.

Growth Hormone Deficiency - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Growth Hormone Deficiency, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency.

Tetanus - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Tetanus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tetanus.

Constipation - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Constipation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Constipation.

Renal Anemia - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Renal Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Renal Anemia.

Polycythemia Vera - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polycythemia Vera, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycythemia Vera.

Pertussis - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Pertussis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pertussis.

Retinoblastoma - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma.

Metabolic Syndrome - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metabolic Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metabolic Syndrome.

Nosocomial Infections - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections.

Female Sexual Dysfunction - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction.

Actinic Keratosis - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Actinic Keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Actinic Keratosis.

Smallpox - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Smallpox, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smallpox.

Retinal Vein Occlusion - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Retinal Vein Occlusion, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion.

Rosacea - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea.

Glomerulonephritis - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Glomerulonephritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glomerulonephritis.

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome.

Polio - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Polio, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polio.

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT).

Fatigue - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue.

Diabetic Neuropathy - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy.